The incompatible crossmatch
- Dennis Goldfinger, MD
Dennis Goldfinger, MD
- Consultant Specialist, MD
- Olive View Medical Center
- Dawn Ward, MD
Dawn Ward, MD
- Assistant Professor, Division of Transfusion Medicine
- David Geffen School of Medicine at UCLA
An essential goal in transfusion medicine is that transfused blood be compatible with the patient. The clinical and serologic evaluation, which allows for the transfusion of the most compatible (or "least incompatible") blood, requires a joint effort between the clinician and the transfusion medicine physician .
However, there are times when all available resources are exhausted and a unit of blood that is not crossmatch compatible must be issued to the patient. The most common of these clinical situations as well as suggestions on how safely to issue and transfuse the best unit of blood available will be reviewed here. General discussions of crossmatching procedures and red cell antigens are presented separately. (See "Pretransfusion testing for red blood cell transfusion" and "Red blood cell antigens and antibodies".)
When blood is ordered for transfusion, a sample of blood is obtained from the patient, and the transfusion service typically performs type and screen and crossmatching tests on the patient's red blood cells (RBCs) and plasma:
●A type test of the patient's RBCs to determine the ABO and Rh types. (See "Pretransfusion testing for red blood cell transfusion", section on 'Interpretation of pretransfusion testing results'.)
●An antibody screen of the patient's plasma to determine if unexpected anti-RBC antibodies are present. (See "Pretransfusion testing for red blood cell transfusion", section on 'Interpretation of pretransfusion testing results'.)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Petz LD. "Least incompatible" units for transfusion in autoimmune hemolytic anemia: should we eliminate this meaningless term? A commentary for clinicians and transfusion medicine professionals. Transfusion 2003; 43:1503.
- Chiaroni J, Gouvitsos J, Dettori I, Ferrera V. How we evaluate panagglutinating sera. Transfusion 2009; 49:1540.
- Petz LD. A physician's guide to transfusion in autoimmune haemolytic anaemia. Br J Haematol 2004; 124:712.
- Kleinman S, Nelson R, Smith L, Goldfinger D. Positive direct antiglobulin tests and immune hemolytic anemia in patients receiving procainamide. N Engl J Med 1984; 311:809.
- Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol 2005; 42:137.
- Petz L. Blood transfusion in acquired hemolytic anemias. In: Clinical Practice of Transfusion Medicine, Petz L (Ed), Churchill Livingstone, New York 1996. p.469.
- Gilliland B. Autoimmune hemolytic anemia. In: Principles of Transfusion Medicine, Rossi E (Ed), Williams Wilkins, Baltimore 1996. p.101.
- Salama A, Berghöfer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet 1992; 340:1515.
- Sokol RJ, Hewitt S, Booker DJ, Morris BM. Patients with red cell autoantibodies: selection of blood for transfusion. Clin Lab Haematol 1988; 10:257.
- Garratty G. Mechanisms of immune red cell destruction, and red cell compatibility testing. Hum Pathol 1983; 14:204.
- Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008; 48:2069.
- Harmening DM. Modern blood banking and transfusion practices, 5th ed, F.A. Davis Company, Philadelphia 2005.
- Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion 1999; 39:763.
- Pineda AA, Vamvakas EC, Gorden LD, et al. Trends in the incidence of delayed hemolytic and delayed serologic transfusion reactions. Transfusion 1999; 39:1097.
- Schonewille H, Brand A. Does an alloimmune response to strong immunogenic red blood cell antigens enhance a response to weaker antigens? Transfusion 2008; 48:958.
- Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 2009; 114:4279.
- Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009; 49:505.
- Schonewille H, de Vries RR, Brand A. Alloimmune response after additional red blood cell antigen challenge in immunized hematooncology patients. Transfusion 2009; 49:453.
- Nordvall M, Dziegiel M, Hegaard HK, et al. Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion 2009; 49:2070.
- Tormey CA, Stack G. The characterization and classification of concurrent blood group antibodies. Transfusion 2009; 49:2709.
- Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. Transfusion 1997; 37:357.
- Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41:1086.
- Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med 2005; 129:190.
- Menitove J. The Hardy-Weinberg principle: Selection of compatible blood based on mathematic principles. In: Numbers for Blood Bankers, Fridey J (Ed), American Association of Blood Banks, Bathesda 1995. p.4.
- Arndt PA, Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting the clinical significance of blood group alloantibodies. Transfusion 2004; 44:1273.
- Noble AL, Poole GD, Anderson N, et al. Predicting the severity of haemolytic disease of the newborn: an assessment of the clinical usefulness of the chemiluminescence test. Br J Haematol 1995; 90:718.
- Mazzara R, Lozano M, Salmerón JM, et al. Transfusion of incompatible RBCs to a patient with alloanti-Kp(b). Transfusion 2001; 41:611.
- Petz L, Garratty G. Immune hemolytic anemias, Churchill Livingstone, New York 2004.
- Sokol RJ, Booker DJ, Stamps R. The pathology of autoimmune haemolytic anaemia. J Clin Pathol 1992; 45:1047.
- Blackall DP. How do I approach patients with warm-reactive autoantibodies? Transfusion 2011; 51:14.
- Petz LD. Autoimmune hemolytic anemia. Hum Pathol 1983; 14:251.
- Øyen R, Angeles ML. A simple screening method to evaluate the presence of alloantibodies with concomitant warm autoantibodies. Immunohematology 1995; 11:85.
- Branch DR, Petz LD. A new reagent (ZZAP) having multiple applications in immunohematology. Am J Clin Pathol 1982; 78:161.
- Leger RM, Garratty G. Evaluation of methods for detecting alloantibodies underlying warm autoantibodies. Transfusion 1999; 39:11.
- Cid J, Ortín X, Pinacho A, et al. Use of polyethylene glycol for performing autologous adsorptions. Transfusion 2005; 45:694.
- Garratty G, Petz LD. Approaches to selecting blood for transfusion to patients with autoimmune hemolytic anemia. Transfusion 2002; 42:1390.
- Svensson AM, Bushor S, Fung MK. Case report: exacerbation of hemolytic anemia requiring multiple incompatible RBC transfusions. Immunohematology 2004; 20:177.
- Shirey RS, Boyd JS, Parwani AV, et al. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion 2002; 42:1435.
- Reid ME. Applications of DNA-based assays in blood group antigen and antibody identification. Transfusion 2003; 43:1748.
- Silvergleid AJ, Wells RF, Hafleigh EB, et al. Compatibility test using 51chromium-labeled red blood cells in crossmatch positive patients. Transfusion 1978; 18:8.
- Mayer K, Bettigole RE, Harris JP, D'Amaro J. Test in vivo to determine donor blood compatibility. Transfusion 1968; 8:28.
- Anstee DJ. Red cell genotyping and the future of pretransfusion testing. Blood 2009; 114:248.
- CROSSMATCHING OVERVIEW
- INITIAL EVALUATION AND MANAGEMENT
- Communication between clinical team and transfusion team
- Patient history
- Immediate management
- Common alloantibodies
- - Alloantibody persistence and evanescence
- Multiple alloantibodies
- - Sickle cell disease
- Alloantibodies to high frequency antigens
- Delayed hemolytic transfusion reaction
- Identification of blood for transfusion
- - Patients with multiple alloantibodies
- - Alloantibody to a high frequency antigen
- Warm autoimmune hemolytic anemia
- Cold agglutinin disease
- Drug-induced AIHA
- AIHA and concurrent alloantibodies
- Identification of blood for transfusion
- In vivo crossmatch
- ABO DISCREPANCIES